Kripa Devarakonda

Can you talk about expectations from RACE101 in first-line cell lung cancer that's expected later this year

Was there anything in particular that you think might have a significant impact on you know, either the timelines

with the label change in EU and potentially a change in the U.S. as well. How do you see the peak opportunity now

Any update on when we might see data? We've heard the potential to see data in June at a conference

how do you see Pfizer's portfolio in breast cancer evolve over the next few years?